Xvivo Perfusion AB
Research Xvivo Perfusion AB (XVIVO) on Bullrun: valuation model: 40.8% overvalued, market cap SEK 8.58B, P/E 96.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXVIVO
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal40.8% overvalued
- Market capSEK 8.58B
- P/E96.9
- Financial periodQ2 2026
- RevenueSEK 238.99M
- Net incomeSEK 16.28M
- Gross margin70.9%
Valuation Snapshot
Bullrun's latest valuation model marks Xvivo Perfusion AB as 40.8% overvalued; latest market cap is SEK 8.58B; P/E is 96.9.
Peer valuation comparison
Latest P/E is 96.94x versus a Healthcare sector median of 24.46x (296.3% above).
Latest P/E is 96.94x versus a Sweden median of 18.57x (422.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 812.17M | SEK 25.16M | n/a | 73.8% | n/a | SEK 292.09M | SEK 124.72M | SEK 2.11B |
| FY2024 | SEK 822.41M | SEK 172.19M | n/a | 75.0% | n/a | SEK 415.52M | SEK 34.04M | SEK 2.16B |
| FY2023 | SEK 597.54M | SEK 91.82M | n/a | 74.5% | n/a | SEK 546.09M | n/a | n/a |
| FY2022 | SEK 415.29M | SEK 18.43M | n/a | 71.5% | n/a | SEK 246.55M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | SEK 8.58B | 96.9 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Xvivo Perfusion AB overvalued or undervalued?
Bullrun's valuation model currently marks Xvivo Perfusion AB as 40.8% overvalued.
What is Xvivo Perfusion AB's market cap?
Xvivo Perfusion AB's market capitalization is SEK 8.58B.
What is Xvivo Perfusion AB's P/E ratio?
Xvivo Perfusion AB's price-to-earnings (P/E) ratio is 96.9.
What does Xvivo Perfusion AB do?
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments.